Cell-Free circulating DNA (cfDNA) is an incredible source of information on the health status of humans and animals. This largely untapped source of knowledge can be utilized to detect sepsis earlier than ever before and independent of the causing pathogen.
Background
Technology
acib specializes in extracting, analysing, and interpreting cfDNA, offering valuable insights for various applications. We isolate and purify cfDNA from blood samples with high precision, separating it from other molecules like RNA and proteins. This purified cfDNA serves as a “liquid biopsy,” offering information about your health without traditional tissue biopsies.Through advanced bioinformatics, we identify genuine cfDNA and differentiate true cfDNA from cell debris to ensure accurate results. We map the DNA and compare the cfDNA to the complete genome, pinpointing abundance differences in distribution. We then identify key patterns and specific DNA sequences associated
with diseases, enabling the development of a powerful diagnostic tool. Applying our in-house developed analysis method, we are able to detect sepsis with a balanced accuracy higher than 85%.
Offer
acib is looking for partners to further co-develop a qPCR-based diagnostic tool for the pathogen-independent diagnosis of sepsis. This assay already demonstrates a high balanced accuracy of over 85 % on the same daythe blood culture sample is taken according to the Sepsis-3 definition. Reach out to explore partnership opportunities and be part of our innovative approach to sepsis diagnostics.
